The potential involvement of P2X7 receptor in COVID-19 pathogenesis: A new therapeutic target?

dc.creatorPacheco, Paulo A. F.
dc.creatorFaria, Robson X.
dc.date2021-12-12T14:30:11Z
dc.date2021-12-12T14:30:11Z
dc.date2020
dc.date.accessioned2023-09-26T23:11:46Z
dc.date.available2023-09-26T23:11:46Z
dc.identifierPACHECO, Paulo A. F. ; FARIA, Robson X. The potential involvement of P2X7 receptor in COVID-19 pathogenesis: A new therapeutic target? Scandinavian Journal of Immunology, v. 93, n. 2, p. 1-9, Aug. 2020.
dc.identifier0300-9475
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/50315
dc.identifier10.1111/sji.12960
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8887895
dc.descriptionCoronavirus disease 2019 (COVID-19) pathogenesis remains under investigation. Growing evidence indicates the establishment of a hyperinflammatory response, characterized by sustained production of cytokines, such as IL-1β. The release and maturation of this cytokine are dependent on the activation of a catalytic multiprotein complex, known as “inflammasome”. The most investigated is the NLRP3 inflammasome, which can be activated by various stimuli, such as the recognition of extracellular ATP by the P2X7 receptor. Based on the recent literature, we present evidence that supports the idea that the P2X7R/NLRP3 axis may be involved in the immune dysregulation caused by the SARS-CoV-2 infection.
dc.formatapplication/pdf
dc.languageeng
dc.publisherWiley
dc.rightsopen access
dc.subjectCOVID-19
dc.subjectEnvolvimento portencial
dc.subjectReceptor P2X7
dc.subjectPatogênese
dc.subjectAlvo terapêutico
dc.subjectP2X7 receptor
dc.subjectPathogenesis
dc.subjectPotential involvement
dc.subjectTherapeutic target
dc.subjectCOVID-19
dc.titleThe potential involvement of P2X7 receptor in COVID-19 pathogenesis: A new therapeutic target?
dc.typeArticle


Este ítem pertenece a la siguiente institución